Literature DB >> 17134630

Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease.

Jian Liu1, Christopher T Sempos, Richard P Donahue, Joan Dorn, Maurizio Trevisan, Scott M Grundy.   

Abstract

To determine if non-high-density lipoprotein (HDL) cholesterol is a more useful predictor of coronary heart disease (CHD) risk than low-density lipoprotein (LDL) cholesterol and if very-low-density lipoprotein (VLDL) cholesterol is an independent predictor of CHD risk, data from the Framingham Heart Study (2,693 men, 3,101 women) were used for this analysis. All subjects were aged > or =30 years and free of CHD at baseline, and incident CHD was the end point (618 men, 372 women). Cox proportional-hazards models were used to assess the risk for CHD (relative risks and 95% confidence intervals) on the basis of the joint distribution of LDL cholesterol and non-HDL cholesterol (in milligrams per deciliter), as well as LDL cholesterol, non-HDL cholesterol, and VLDL cholesterol as continuous variables. After multivariate adjustment, within non-HDL cholesterol level, no association was found between LDL cholesterol and the risk for CHD, whereas within LDL cholesterol levels, a strong positive and graded association between non-HDL cholesterol and risk for CHD was observed. When the analysis was repeated within triglyceride levels (<200 vs > or =200 mg/dl), the risk pattern did not change significantly. Also, VLDL cholesterol was found to be a significant predictor of CHD risk after adjusting for LDL cholesterol at triglyceride levels of > or =200 or <200 mg/dl. In conclusion, these results suggest that non-HDL cholesterol level is a stronger predictor of CHD risk than LDL cholesterol; that is, VLDL cholesterol may play a critical role in the development of CHD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17134630     DOI: 10.1016/j.amjcard.2006.06.032

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  69 in total

1.  Serum non-high-density lipoprotein cholesterol (non-HDL-C) levels and cardiovascular mortality in chronic hemodialysis patients.

Authors:  Yoshihisa Echida; Tetsuya Ogawa; Kuniaki Otsuka; Yoshitaka Ando; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-02-29       Impact factor: 2.801

2.  A Comparative Overview of Prescription Omega-3 Fatty Acid Products.

Authors:  Matthew K Ito
Journal:  P T       Date:  2015-12

3.  Relationship between serum cholesterol and indices of erythrocytes and platelets in the US population.

Authors:  Michael B Fessler; Kathryn Rose; Yanmei Zhang; Renee Jaramillo; Darryl C Zeldin
Journal:  J Lipid Res       Date:  2013-09-02       Impact factor: 5.922

Review 4.  Consensus statement on management of dyslipidemia in Indian subjects.

Authors:  K Sarat Chandra; Manish Bansal; Tiny Nair; S S Iyengar; Rajeev Gupta; Subhash C Manchanda; P P Mohanan; V Dayasagar Rao; C N Manjunath; J P S Sawhney; Nakul Sinha; A K Pancholia; Sundeep Mishra; Ravi R Kasliwal; Saumitra Kumar; Unni Krishnan; Sanjay Kalra; Anoop Misra; Usha Shrivastava; Seema Gulati
Journal:  Indian Heart J       Date:  2014-12-24

5.  Rosuvastatin in diabetic hemodialysis patients.

Authors:  Hallvard Holdaas; Ingar Holme; Roland E Schmieder; Alan G Jardine; Faiez Zannad; Gudrun E Norby; Bengt C Fellström
Journal:  J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 10.121

6.  Supplementation of Bacillus sp. DU-106 reduces hypercholesterolemia and ameliorates gut dysbiosis in high-fat diet rats.

Authors:  Jianzhao Huang; Nan Xiao; Yiying Sun; Shanshan Wu; Wenni Tian; Yujian Lai; Pan Li; Bing Du
Journal:  Appl Microbiol Biotechnol       Date:  2020-10-31       Impact factor: 4.813

Review 7.  Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.

Authors:  Peter Alagona
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

8.  Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population.

Authors:  Jessica W Nelson; Elizabeth E Hatch; Thomas F Webster
Journal:  Environ Health Perspect       Date:  2010-02       Impact factor: 9.031

9.  The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period.

Authors:  Peter Weeke; Charlotte Andersson; Emil L Fosbøl; Bente Brendorp; Lars Køber; Arya M Sharma; Nick Finer; Philip T James; Ian D Caterson; Richard A Rode; Christian Torp-Pedersen
Journal:  BMC Endocr Disord       Date:  2010-02-26       Impact factor: 2.763

Review 10.  Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.

Authors:  N John Bosomworth
Journal:  Can Fam Physician       Date:  2013-11       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.